Agios Pharmaceuticals, Inc. - Common Stock — 현금 흐름 (NASDAQ:AGIO)

Financials

영업활동으로 인한 현금 -290.76 M-407.32 M-309.48 M-296.06 M-389.84 M-372.98 M -380.41 M 투자 활동으로 인한 현금 75.75 M1.25 B243.26 M239.57 M363.44 M377.18 M 405.91 M 재무활동으로 인한 현금 261.52 M-765.77 M2.35 M5.43 M14.44 M8.68 M 9.13 M 잉여 현금 흐름 -290.76 M-407.32 M-309.48 M-296.06 M-389.84 M-377.29 M -384.73 M

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

AGIO

Financials

Agios Pharmaceuticals, Inc. - Common Stock

뉴스

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class (AGIO)

Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?

AGIO's Pyrukynd Gets Approval for Thalassemia in Europe

Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease

AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum

Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline

Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline

Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade)

Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock